港股異動丨和鉑醫藥一度飆升27%,獲阿斯利康1.05億美元入股且達成戰略合作
和鉑醫藥-B(2142.HK)盤初一度飆升27.71%,報10港元,股價創2021年11月以來新高。消息面上,和鉑醫藥上週五盤後宣佈,公司擬向阿斯利康配發及發行認購股份,後者將以每股1.38美元(相當於每股約10.74港元)的價格進行認購,較上週五收盤價溢價37%。本次阿斯利康認購的股份,將佔和鉑醫藥總股本(不包括庫存股份)的9.15%。認購所得款項約爲1.05億美元(約8.19億港元),將用於公司的研發、營運及一般營運資金需求。同日,和鉑醫藥宣佈與阿斯利康達成全球戰略合作。雙方將共同研發針對免疫性疾病、腫瘤及其他多種疾病的新一代多特異性抗體療法。此次戰略合作內容涵蓋基於和鉑醫藥專有的Harbour Mice全人源抗體技術平臺在多治療領域的多項目授權許可協議,以及阿斯利康對和鉑醫藥的1.05億美元股權投資。根據協議條款,阿斯利康將獲得兩項臨牀前免疫學項目的授權許可選擇權,並將提名更多靶點由和鉑醫藥開發新一代多特異性抗體療法。阿斯利康可行使選擇權以推進這些項目進入臨牀開發階段。戰略合作初期將聚焦現有研發項目,未來還將繼續拓展至更多項目合作。和鉑醫藥將獲得總計1.75億美元的首付款、近期里程碑付款和額外新增項目的選擇權行使費,以及最高達44億美元的研發及商業里程碑付款,外加基於未來產品淨銷售額的分級特許權使用費。此外,雙方還可選擇在未來五年內將更多項目納入合作範圍,並可在雙方同意的情況下將協議期限再延長五年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.